Home › Therapeutic areas › Neurology

Neurology (89 companies · 63 conditions)

Conditions

Multiple Sclerosis 17 Amyotrophic Lateral Sclerosis 16 Rare Alzheimer's Disease 14 Major Depressive Disorder 13 Parkinson's Disease 13 Duchenne Muscular Dystrophy 10 Rare Epilepsy 8 Schizophrenia 8 Bipolar Disorder 7 Myasthenia Gravis 7 Rare Huntington's Disease 6 Rare Frontotemporal Dementia 5 Rare Generalized Anxiety Disorder 5 Friedreich's Ataxia 4 Rare Lewy Body Dementia 4 Migraine 4 Multiple System Atrophy 4 Rare Myotonic Dystrophy 4 Rare Attention Deficit Hyperactivity Disorder 3 Autism Spectrum Disorder 3 Chronic Pain 3 Dravet Syndrome 3 Rare Post-Traumatic Stress Disorder 3 Rett Syndrome 3 Rare Substance Use Disorder 3 Facioscapulohumeral Muscular Dystrophy 2 Rare Infantile Spasms 2 Rare Narcolepsy 2 Rare Progressive Supranuclear Palsy 2 Rare Spinal Cord Injury 2 Stiff Person Syndrome 2 Rare Tourette Syndrome 2 Acute Pain 1 Aneurysmal Subarachnoid Hemorrhage 1 Angelman Syndrome 1 Rare Anorexia Nervosa 1 Charcot-Marie-Tooth Disease Type 2S 1 Rare Chronic Inflammatory Demyelinating Polyneuropathy 1 Rare Chronic Low Back Pain 1 CLN2 Batten Disease 1 Rare Cocaine Use Disorder 1 Delayed Sleep Phase Disorder 1 Dementia-Related Psychosis 1 Essential Tremor 1 Fragile X Syndrome 1 Rare Giant Axonal Neuropathy 1 Rare GNE Myopathy 1 Rare Guillain-Barré Syndrome 1 Insomnia 1 Ischemic Stroke 1 Jet Lag Disorder 1 Lennox-Gastaut Syndrome 1 Rare Limb-Girdle Muscular Dystrophy 1 Rare Motion Sickness 1 Non-24-Hour Sleep-Wake Disorder 1 Non-Fluent Variant Primary Progressive Aphasia 1 Rare Primary Periodic Paralysis 1 Rare Smith-Magenis Syndrome 1 Rare Spinal Bulbar Muscular Atrophy 1 Rare Spinal Muscular Atrophy 1 Rare Spinocerebellar Ataxia 1 Rare Tuberous Sclerosis Complex 1 Rare X-Linked Adrenoleukodystrophy 1 Rare

Companies

Ticker Company Therapeutic areas In Neurology Lead stage Mkt cap Programs
AARD Aardvark Therapeutics DermatologyMetabolic+1 Rare 1 Phase 3 $25.2M 3
ACIU AC Immune Neurology Rare 10 Phase 3 $210M 11
ABOS Acumen Pharmaceuticals Neurology 4 Phase 2 $16.6M 4
ACET Adicet Bio ImmunologyNeurology+2 Rare 1 Phase 1 $26.0M 8
ATHE Alterity Therapeutics Neurology Rare 2 Phase 2 $35.7M 2
ALT Altimmune GI/HepatologyMetabolic+1 1 Phase 3 $298M 3
ANRO Alto Neuroscience Neurology 6 Phase 2 $999M 6
ALMS Alumis DermatologyImmunology+1 1 Phase 3 $628M 5
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 $3.54B 5
ANNX Annexon HematologyNeurology+2 Rare 3 Phase 3 $662M 6
ARVN Arvinas NeurologyOncology Rare 3 Approved $447M 10
ATAI Atai Beckley Neurology 5 Phase 2 $2.73B 5
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 1 Approved $290M 12
AXSM Axsome Therapeutics Neurology Rare 10 Approved $7.15B 15
CABA Cabaletta Bio DermatologyImmunology+2 Rare 1 Phase 2 $220M 8
CAPR Capricor Therapeutics Infectious DiseaseNeurology Rare 1 NDA Submitted $489M 2
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 1 Phase 3 $187M 4
CRVO CervoMed Neurology Rare 4 Phase 2 $22.7M 4
CING Cingulate Neurology 1 NDA Submitted $70.6M 1
CLNN Clene Neurology Rare 3 NDA Submitted $46.4M 5
CGTX Cognition Therapeutics Neurology 2 Phase 2 $59.9M 2
CMPS COMPASS Pathways Neurology 3 NDA Submitted $1.13B 3
CTNM Contineum Therapeutics NeurologyRespiratory Rare 3 Phase 2 $375M 4
COYA Coya Therapeutics Neurology Rare 2 Phase 2 $70.8M 6
CYDY CytoDyn NeurologyOncology 1 Phase 2 $367M 3
DFTX Definium Therapeutics Neurology 4 Phase 3 $4.02B 4
DYN Dyne Therapeutics MetabolicNeurology Rare 7 NDA Submitted $3.00B 10
ELDN Eledon Pharmaceuticals ImmunologyMetabolic+1 Rare 1 Phase 2 $167M 3
ENTA Enanta Pharmaceuticals DermatologyImmunology+2 1 Approved $253M 8
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 2 Approved $1.84B 17
EVMN Evommune DermatologyImmunology+1 1 Phase 2 $290M 6
FBIO Fortress Biotech DermatologyHematology+4 Rare 1 Approved $61.4M 16
GANX Gain Therapeutics MetabolicNeurology Rare 4 Phase 1 $52.5M 5
GHRS GH Research NeurologyWomen's Health 3 Phase 2 $1.25B 4
GRCE Grace Therapeutics Neurology 1 NDA Submitted $36.2M 1
HRMY Harmony Biosciences MetabolicNeurology Rare 12 Approved $1.94B 17
HELP Helus Pharma Neurology 3 Phase 3 $575M 3
IMUX Immunic GI/HepatologyNeurology 2 Phase 3 $116M 4
IMVT Immunovant ImmunologyNeurology Rare 2 Phase 3 $6.87B 4
IXHL Incannex Healthcare NeurologyRespiratory 1 Phase 2 $21.8M 2
INSM Insmed CardiovascularImmunology+3 Rare 2 Approved $26.7B 15
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 7 Approved $4.49B 29
KZIA Kazia Therapeutics NeurologyOncology Rare 1 Phase 2 $60.7M 13
KROS Keros Therapeutics NeurologyOncology Rare 2 Phase 3 $222M 5
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 3 NDA Submitted $297M 6
LRMR Larimar Therapeutics Neurology Rare 1 NDA Submitted $313M 1
LBRX LB Pharmaceuticals Neurology 3 Phase 3 $1.30B 3
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 9 Phase 2 $236M 12
LCTX Lineage Cell Therapeutics MetabolicNeurology+1 Rare 2 Phase 2 $207M 13
LGVN Longeveron CardiovascularNeurology Rare 1 Phase 2 $7.1M 3
MPLT MapLight Therapeutics Neurology 3 Phase 2 $365M 3
MGTX MeiraGTx ImmunologyMetabolic+2 Rare 2 Phase 3 $827M 16
MESO Mesoblast CardiovascularGI/Hepatology+2 Rare 2 Approved $1.54B 5
NGEN NervGen Pharma Neurology 3 Phase 3 $211M 3
NGNE Neurogene Neurology Rare 1 Phase 3 $478M 1
NRSN NeuroSense Therapeutics Neurology Rare 3 Phase 2 $2.9M 3
NAMS NewAmsterdam Pharma CardiovascularMetabolic+1 1 NDA Submitted $2.33B 6
NKTX Nkarta ImmunologyNeurology+1 Rare 1 Phase 1 $89.6M 8
NRXP NRX Pharmaceuticals Neurology Rare 10 Approved $109M 11
NRIX Nurix Therapeutics ImmunologyNeurology+1 1 Phase 3 $1.56B 13
OCS Oculis Holding NeurologyOphthalmology Rare 1 Phase 3 $418M 5
OMER Omeros HematologyNeurology+2 Rare 2 Approved $1.04B 6
OVID Ovid Therapeutics Neurology Rare 3 Phase 2 $419M 4
KTTA Pasithea Therapeutics NeurologyOncology Rare 2 Phase 1 $16.0M 4
PEPG PepGen Neurology Rare 1 Phase 2 $269M 1
DTIL Precision Biosciences Infectious DiseaseMetabolic+1 Rare 2 Phase 1 $197M 5
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 1 Phase 2 $4.8M 7
PMN ProMIS Neurosciences Neurology Rare 7 Phase 1 $28.9M 9
PRQR ProQR Therapeutics MetabolicNeurology Rare 1 Phase 1 $163M 7
RAPP Rapport Therapeutics Neurology 4 Phase 3 $1.41B 6
RLMD Relmada Therapeutics MetabolicNeurology+1 Rare 2 Phase 2 $321M 4
RVPH Reviva Pharmaceuticals CardiovascularDermatology+3 Rare 7 Phase 3 $4.7M 11
SRPT Sarepta Therapeutics NeurologyRespiratory Rare 10 Approved $1.58B 11
SLDB Solid Biosciences CardiovascularNeurology Rare 2 Phase 3 $695M 6
STOK Stoke Therapeutics Neurology Rare 1 Phase 3 $1.73B 2
TSHA Taysha Gene Therapies Neurology Rare 3 Phase 3 $1.30B 4
TGTX Tg Therapeutics Neurology Rare 6 Approved $9.48B 6
TLSA Tiziana Life Sciences ImmunologyNeurology Rare 4 Phase 2 $83.2M 5
RARE Ultragenyx Pharmaceutical CardiovascularMetabolic+1 Rare 1 Approved $1.70B 10
QURE uniQure HematologyMetabolic+1 Rare 2 Approved $1.46B 4
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 16 Approved $230M 27
VKTX Viking Therapeutics MetabolicNeurology Rare 1 Phase 3 $3.43B 9
VOR Vor Biopharma ImmunologyNeurology Rare 1 Phase 3 $1.12B 2
VYGR Voyager Therapeutics MetabolicNeurology Rare 8 Phase 1 $94.6M 9
WVE Wave Life Sciences MetabolicNeurology+1 Rare 2 Phase 2 $560M 5
XNCR Xencor ImmunologyNeurology+1 Rare 1 Approved $2.59B 28
XENE Xenon Pharmaceuticals Neurology Rare 8 NDA Submitted $3.81B 9
XERS Xeris Biopharma MetabolicNeurology Rare 1 Approved $3.07B 4
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 3 NDA Submitted $1.88B 11